In bladder cancer, METTL3 promoted the m6A-mediated maturation of pri-miR221/222, a PTEN antagonist, resulting in loss of cell cycle control and increased proliferation (Han et al., 2019). This evidence concerns the gene METTL3 and urinary bladder cancer.